Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)

March 11, 2026 updated by: Fannie Lajeunesse-Trempe, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)

Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.

A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.

This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:

  1. To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
  2. To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
  3. To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
  4. To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
  5. To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

25000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Canada
    • Quebec
      • Québec, Quebec, Canada, G1V 4G5
        • Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
        • Principal Investigator:
          • Fannie Lajeunesse-Trempe, MD PhD FRCPC
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.

Description

To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:

  1. Be over 18 years of age

  2. Meet at least one of the following five criteria:

    1. Body mass index ≥30 kg/m2 with or without comorbidities (preclinical or clinical obesity);
    2. Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);
    3. History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;
    4. History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;
    5. Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Obesity medicine cohort
This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval
Other: Behavioral and Pharmacological Treatments
Behavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Success or failure of obesity medicine interventions
Time Frame: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another
  1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis
  2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available)
  3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts
  4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts
  5. Mental Health Parameters: As recorded in medical charts
Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Collaborators

Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

June 1, 2051

Study Completion (Estimated)

June 1, 2051

Study Registration Dates

First Submitted

February 27, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-4343

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Behavioral and Pharmacological Treatments

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe